The new American Joint Committee on Cancer (AJCC) guidelines for the staging of melanoma were introduced into clinical practice in 2010 [7]. The two most important distinctions with previous guidelines are the incorporation of the mitotic rate of the primary tumor and the key role of the sentinel lymph node, including methods of analysis, in accurately staging clinically occult nodal disease [8].